Abstract:Background The COVID-19 outbreak represents a significant challenge to international health. Several studies have reported a substantial decrease in the number of patients attending emergency departments with acute coronary syndromes (ACS) and there has been a concomitant rise in early mortality or complications during the COVID-19 pandemic. A modified management system that emphasizes nearby treatment, safety, and protection, alongside a closer and more effective multiple discipline collaborative team was developed by our Chest Pain Center at an early stage of the pandemic. It was therefore necessary to evaluate whether the newly adopted management strategies improved the clinical outcomes of ACS patients in the early stages of the COVID-19 pandemic. Methods Patients admitted to our Chest Pain Center from January 25th to April 30th, 2020 based on electronic data in the hospitals ACS registry, were included in the COVID-19 group. Patients admitted during the same period (25 January to 30 April) in 2019 were included in the pre-COVID-19 group. The characteristics and clinical outcomes of the ACS patients in the COVID-19 period group were compared with those of the ACS patients in the pre-COVID-19 group. Multivariate logistic regression analyses were used to identify the risk factors associated with clinical outcomes. Results The number of patients presenting to the Chest Pain Center was reduced by 45% ( p = 0.01) in the COVID-19 group, a total of 223 ACS patients were included in the analysis. There was a longer average delay from the onset of symptom to first medical contact (FMC) (1176.9 min vs. 625.2 min, p = 0.001) in the COVID-19 period group compared to the pre-COVID-19 group. Moreover, immediate percutaneous coronary intervention (PCI) (80.1% vs. 92.3%, p = 0.008) was performed less frequently on ACS patients in the COVID-19 group compared to the pre-COVID-19 group. However, more ACS patients received thrombolytic therapy (5.8% vs. 0.6%, p = 0.0052) in the COVID-19 group than observed in the pre-COVID-19 group. Interestingly, clinical outcome did not worsen in the COVID-19 group when cardiogenic shock, sustained ventricular tachycardia, ventricular fibrillation or use of mechanical circulatory support (MCS) were compared against the pre-COVID-19 group (13.5% vs. 11.6%, p = 0.55). Only age was independently associated with composite clinical outcomes (HR = 1.3; 95% CI 1.12–1.50, p = 0.003). Conclusion This retrospective study showed that the adverse outcomes were not different during the COVID-19 pandemic compared to historical control data, suggesting that newly adopted management strategies might provide optimal care for ACS patients. Larger sample sizes and longer follow-up periods on this issue are needed in the future.

A Treatment Strategy for Acute Myocardial Infarction and Personal Protection for Medical Staff During the COVID-19 Epidemic: the Chinese Experience

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic

2023 Chinese Expert Consensus on the Impact of COVID-19 on the Management of Cardiovascular Diseases

[Consensus of Chinese Experts on Diagnosis and Treatment Processes of Acute Myocardial Infarction in the Context of Prevention and Control of COVID-19 (first Edition)].

Management of acute coronary syndrome in the context of coronavirus disease 2019

Management and Outcomes of Patients with STEMI During the COVID-19 Pandemic in China.

Management strategies and outcomes of acute coronary syndrome (ACS) during Covid-19 pandemic

Chinese Society of Interventional Radiology Expert Consensus on the prevention and control of COVID-19 in interventional radiology procedures (first edition)

Effect of COVID-19 Pandemic on Acute Coronary Syndrome Clinical Practice Patterns: Findings from a Multicenter Clinician Survey in China

Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP)

Clinical Characteristics and Current Treatment of Critically Ill Patients with COVID-19 Outside Wuhan, China: A Multicenter, Retrospective, Observational Study

Impact of the COVID-19 Pandemic on ST-Elevation Myocardial Infarction Management in Hunan Province, China: A Multi-Center Observational Study

Safety measures for COVID-19 do not compromise the outcomes of patients undergoing primary percutaneous coronary intervention: a single center retrospective study

Countermeasures and treatment for aortic acute syndrome with 2019 coronavirus disease

Effect of COVID-19 outbreak on the treatment time of patients with acute ST-segment elevation myocardial infarction

Expert consensus on prevention and cardiopulmonary resuscitation for cardiac arrest in COVID-19

Triage for Potential Percutaneous Coronary Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic

Letter: Strategies for Prevention and Control of 2019 Novel Coronavirus Infection Among Medical Staff

Risk-adapted Treatment Strategy For COVID-19 Patients.

The Impact of COVID-19 on Short-Term Prognosis of ST-segment Elevation Myocardial Infarction Patients Receiving Primary Percutaneous Coronary Intervention in Wuhan China

[Countermeasures and Treatment for Aortic Acute Syndrome with Novel Coronavirus Pneumonia].